Navigation Links
Therapeutic DNA Vaccine Company Inovio Biomedical Reports Second Quarter 2008 Financial Results
Date:8/7/2008

NA vaccine delivered with electroporation compared to a similar amount of DNA delivered using a DNA injection alone. The result suggested that electroporation provides a strong adjuvant effect capable of priming the immune system, partially explaining the apparent enhancement that electroporation has provided in enhancing the potency of DNA vaccines in humans. Tripep AB reported preliminary results from the first patient to complete treatment with Tripep's therapeutic hepatitis C virus (HCV) vaccine, ChronVac-C(R), which was delivered using Inovio's electroporation-based DNA delivery system. In this phase I/II clinical study, the treatment has been shown to be tolerable and safe. In samples taken before, during and after treatment, preliminary results from the first two patients in the intermediate dose group to complete treatment against hepatitis C virus infection showed that the viral levels in blood decreased up to 87% and 98%, respectively, during treatment. Simultaneous activation of the patients' T-cell responses to the hepatitis C virus was recorded in conjunction with the viral load reductions. Pre-clinical results from two proprietary plasmid DNA-based universal influenza vaccine candidates using the company's proprietary electroporation delivery technology and, specifically, a new intradermal device, showed that 100% of immunized mice given a lethal challenge of highly pathogenic H5N1 influenza virus (A/Vietnam/1203/04) survived and showed only minor weight loss. These experimental universal vaccines are based on conserved genes common to multiple strains of seasonal influenza and even potential pandemic influenza, suggesting they may have the possibility to provide widespread protection against such viruses. In addition, we entered into a license agreement with Advanced BioScience Laboratories, Inc. (ABL) so that ABL may conduct certain internal research on DNA vaccines delivered using electroporation and to offer electroporation delivery of DNA vaccines
'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Stiefel Laboratories Completes Acquisition of Barrier Therapeutics
2. Nektar Therapeutics Announces Second Quarter 2008 Results
3. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
4. InteKrin Therapeutics Announces $20 Million Series C Financing
5. Transition Therapeutics Announces No Material Change
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on August 8
7. DIA/AAPS Co-Sponsored Conference to Examine the Immunogenicity of Therapeutic Proteins
8. Cell Therapeutics, Inc. Announces $12 Million Equity Line of Credit
9. Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeutics, Inc.
10. Neurotherapeutics presents special issue on new treatments for Alzheimers disease
11. Horizon Therapeutics Names Timothy P. Walbert as President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Therapeutic DNA Vaccine Company Inovio Biomedical Reports Second Quarter 2008 Financial Results 
(Date:4/18/2014)... new medical-testing device is being prepped to enter ... improve diagnosis of certain diseases in remote areas, ... series of investigations aboard the International Space Station ... the space-tested concept of capillary flow to diagnose ... David Kelso, Ph.D., a researcher at Northwestern University ...
(Date:4/18/2014)... Johns Hopkins University School of Medicine researchers have been ... for diabetes, Novo Nordisk announced this month. Of the ... and Obesity Biologics Science Forum Program, only four projects ... Hopkins researchers. They are Jonathan Powell, M.D., Ph.D.; G. ... , Jonathan Powell, a professor of oncology, will use ...
(Date:4/18/2014)... Fraser University psychologists have made a brain-related discovery ... attention-deficit disorders. , This discovery opens up the ... or suppress a specific brain activity that the ... , The Journal of Neuroscience has ... John McDonald, an associate professor of psychology and ...
(Date:4/18/2014)... Northwestern Medicine scientists could lead to potential new treatments ... with scleroderma. , Fibrosis, or scarring, is a ... skin and lungs can lead to serious organ damage ... new therapeutic options centers on findings made by Swati ... the role that a specific protein plays in promoting ...
(Date:4/17/2014)... first genetic variant specifically associated with the risk ... 10-15 per cent of all breast cancer cases. ... cancer sub-type, called invasive lobular carcinoma, gives researchers ... particular kind of breast cancer, which can be ... (Thursday) in the journal PloS Genetics , ...
Breaking Medicine News(10 mins):Health News:Space-tested fluid flow concept advances infectious disease diagnoses 2Health News:Space-tested fluid flow concept advances infectious disease diagnoses 3Health News:Scientists discover brain's anti-distraction system 2Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3
... Weight loss improves the sexual health of obese men with ... placed 31 obese men with type 2 diabetes on either ... diet meant to decrease calorie intake by 600 calories a ... to an easing of erectile dysfunction and improved sexual desire ...
... People living in a region of the southeastern United States ... higher rates of stroke deaths than the rest of the ... risk for sepsis, a severe illness in which bacteria overwhelms ... sepsis across the United States," said Dr. Henry Wang, associate ...
... University of Massachusetts Medical School have uncovered a novel ... immune response for malaria. Activation of this pathway appears ... by the immune system that may contribute to inflammation ... part in susceptibility for the most common and lethal ...
... , THURSDAY, Aug. 4 (HealthDay News) -- A ... comfortable using the clot-busting drug tissue plasminogen activator (tPA) to ... finds. An ischemic stroke is caused by blocked blood ... of neurology residents who say they,re comfortable using tPA rose ...
... have completed a comprehensive map of genetic mutations occurring ... The findings, reported in the Aug. 4 issue ... biological cause of the tumors, they say. To ... seven oligodendroglioma tissue samples, and focused attention on recurring ...
... the United States spend nearly four times as much dealing ... Most of the difference stems from the fact that Canadian ... multiple payers in the United States. These findings are ... -- the result of a research collaboration among Weill Cornell ...
Cached Medicine News:Health News:U.S. 'Stroke Belt' May Also Be 'Sepsis Belt' 2Health News:Targeting innate immunity in malaria 2Health News:Targeting innate immunity in malaria 3Health News:More Neurology Residents Using Clot-Busting Drug for Stroke 2Health News:Johns Hopkins scientists map genes for common form of brain cancer 2Health News:Johns Hopkins scientists map genes for common form of brain cancer 3Health News:US physician practices spend 4 times Canadian practices 2Health News:US physician practices spend 4 times Canadian practices 3
(Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
(Date:1/15/2014)... BEACH GARDENS, Fla. , Jan. 15, 2014  In an unprecedented ... difficile and TB in ambulances and other transport vehicles, an advanced ... used by rescue personnel for the first time. ... in contact with these deadly pathogens, West Palm Beach ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
... Corporation (NASDAQ: HSKA ), a provider of ... today announced that Robert Grieve, Heska,s Chairman and CEO, will ... (PT), on March 14, 2012, Salon 1, Burgandy Track.  The ... Carlton, 1 Ritz Carlton Drive, Dana Point, California.  Dr. Grieve ...
... BETHESDA, Md., Feb. 23, 2012  Northwest Biotherapeutics (OTC.BB: NWBO) ... clinical trial sites open and recruiting across the United ... DCVax®-L immune therapy for Glioblastoma multiforme (GBM), the most ... milestone ahead of schedule, as the Company had projected ...
Cached Medicine Technology:Heska to Present at the 24th Annual ROTH Conference 2NW Bio Reaches 30 Clinical Trial Sites Ahead of End-of-Q1 Projection 2NW Bio Reaches 30 Clinical Trial Sites Ahead of End-of-Q1 Projection 3
Cholesterol/HDL with 200 tests....
Intended for the in vitro precipitation of very low density and low density lipoproteins in serum or plasma. Single vial, dry powder precipitating reagent. Total cholesterol reagent not included....
... Intended for the quantitative ... plasma. Two vials, dry ... alphaketoglutarate. Uses NADPH to ... plasma compounds. Reaction: Enzymatic, ...
... the quantitative determination of ... vials, dry powder reagents. ... NADPH to eliminate interferences ... Reaction: Enzymatic, endpoint. Wavelength: ...
Medicine Products: